Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06922591 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

A Phase 1 study of Lung Cancer and NSCLC, sponsored by Tango Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
183
Enrollment target
12
Study locations

NCT06922591 is a Phase 1 study of Lung Cancer and NSCLC that is actively recruiting participants, run by Tango Therapeutics. The registered enrollment target is 183 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (80% lower). The trial reports 12 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06922591, a Phase 1 study of Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Tango Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
183 participants
Enrollment target
12
Study locations

Study Summary

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

Conditions Studied

Lung Cancer NSCLC Thoracic Cancer PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Metastatic PDAC RAS Mutation MTAP Deletion

Interventions

  • DRUG mFOLFIRINOX
  • DRUG RMC-6236
  • DRUG TNG462
  • DRUG RMC-9805
  • DRUG gemcitabine/nab-paclitaxel

Study Locations (12)

New York

  • NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • University of Texas MD Anderson Cancer Center - Houston
  • NEXT Dallas - Irving

Arizona

  • Mayo Clinic Scottsdale - Scottsdale

Colorado

  • Sarah Cannon Research Institute Denver - Denver

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Indiana

  • University of Indiana - Indianapolis

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic Cancer Center - Rochester

Trial Details

FieldValue
Enrollment Target 183 participants
Start Date 2025-05-31
Est. Completion 2027-12
Phase Phase 1

Sponsor

Tango Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06922591

The ClinicalTrials.gov registry entry for NCT06922591 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Tango Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which mFOLFIRINOX is the first listed.

NCT06922591 reports 12 study locations spanning 10 distinct geographic areas - top geographies include New York, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT06922591 about?

NCT06922591 is a clinical study titled "Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients". TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and ...

What is the current status of trial NCT06922591?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2025-05-31. Estimated completion is 2027-12.

What conditions does trial NCT06922591 study?

This clinical trial studies the following conditions: Lung Cancer, NSCLC, Thoracic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic.

What interventions are being tested in trial NCT06922591?

The interventions under investigation include: mFOLFIRINOX (DRUG), RMC-6236 (DRUG), TNG462 (DRUG), RMC-9805 (DRUG), gemcitabine/nab-paclitaxel (DRUG).

Who is sponsoring clinical trial NCT06922591?

This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06922591 being conducted?

This trial has 12 study locations across Arizona, Colorado, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

NSCLC

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.